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New reversed-phase high-performance liquid chromatography method has been developed and validated for the 
identification of impurity in calcium orotatedihydrate (CaOD) drug. The developed method has been achieved superior 
resolution between the impurity and CaOD using Alltima C-18 column (250 X 4.6 mm, 5 µm). The method has been 
established by isocratic mobile phase comprising of 0.01 mol/L of potassium dihydrogen orthophosphate, pH adjusted 
to 2.7 with orthophosphoric acid and acetonitrile in a ratio of 98:2 v/v. The eluted impurity at the retention time of 
6.02 min has so far not been reported in earlier methods of analysis. According to International council for 
harmonization guidelines, the method has been validated with respect to accuracy, precision, specificity, linearity, 
range, robustness, system suitability, limit of detection and limit of quantification. The percentage recovery of CaOD 
and uracil is found in the range between 98% and 102%. The linearity data has shown that the method is found to be 
linear for CaOD and uracil from 25% to 150% level and the correlation coefficient is found to be more than 0.999. The 
reported method is not affected by small but deliberate changes in the parameters of the method.  
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In general, human body demands calcium supplement 
that helps to build strong bones and prevents 
osteoporosis
1-3
. In order to maintain the normal 
functioning of cells, nerves, bones, muscles etc. one 
should have the calcium content as per the 
recommended dietary allowance according to their 
age. Suppose there is a lack of calcium in the blood, 
then the body will consume calcium from bones, and 
thus reduces the strength of bones
4-5
. The calcium 
content in our body is helped to prevent weight 
gain and sustaining healthy weight
6-8
. The effects 
of reduced calcium levels indicates emergency 
starvation mode and starts to leach calcium into the 
bloodstream. Orotic acid known as pyrimidine 
carboxylic acid supports the transport of calcium 
through cellular membrane structures which facilitates 
the intracellular uptake of calcium, particularly in 
bone
9
. Calcium orotate is a source of superior 
calcium supplement and absolutely free from side 
effects. It is an essential raw material for making 
the genetic substances deoxyribonucleic acid and 
ribonucleic acid. 
Calcium orotatedihydrate (CaOD) is also a 
calcium supplement which helps in the 
maintenance of healthy cartilage. CaOD is 
chemically termed as calcium 1,2,3,6-tetrahydro-
2,6-dioxopyrimidine-4-carboxylate and it is a 
calcium salt of orotic acid. The appearance of 
CaOD is a white to almost white crystalline 
powder with very slightly soluble in water and 
practically insoluble in alcohols. The usage of 
CaOD drug includes i) hip joint plastic surgery, ii) 
hypoparathyroidism, iii) premenstrual syndrome, 
iv) controlling weight, v) prevent low blood
calcium level, etc. Since CaOD has high affinity
to penetrate complex cellular membrane, it is
generally suggested as calcium supplement for
people who find it problematic to get sufficient
calcium, nursing mothers and pregnant women
10-12
.
This medication is also used to treat or prevent
low blood calcium levels in people who do not get
enough calcium from their diets. The usage of
CaOD drug to regain healthy bone from
osteoporosis is represented in Fig. 1. The drug
CaOD is manufactured by two step processes in
which the first step, uracil is converted into orotic
acid and the second step yields CaOD by treating
the orotic acid with calcium chloride.




Investigation of impurity profile in a drug 




liquid chromatography (HPLC) is a widely used 
instrument to analyse the compound purity and 
profile comprising of both known and unknown 
impurities
17-22
. The literature survey reveals that 
there is no method available for the quantification 
of impurity exists in CaOD bulk drug. Since, the 
drug is not included in any official pharmacopeia, 
an attempt was taken to develop a simple cost 
effective method for quantification of impurity in 
CaOD drug and also the method was validated 
according to the International council for 
harmonization (ICH) guidelines. The developed 
RP-HPLC analytical method is rapid, accurate, 
precise, and reproducible. Hence, the method can 
be applied for routine quality control analysis for 
the estimation of impurity in CaOD bulk drug. 
 
Materials and Methods 
Reagents and Instrumentation 
Potassium dihydrogen orthophosphate (KH2PO4) 
and orthophosphoric acid were purchased from 
Merck India Ltd. Uracil was purchased from Sigma 
Aldrich Co. Calcium orotatedihydrate (CaOD) was 
procured from the market in India which was 
manufactured by renowned manufacturing 
company. HPLC grade acetonitrile and water were 
received from RANKEM. 
Agilent HPLC system (Model: 1220) equipped 
with a UV detector and binary pump is used to 
investigate the related substance analysis of CaOD 
drug. The instrument has an auto injection facility 
and OpenLab CDS software was used to integrate 
the chromatograms. In order to determine the best 
conditions for resolving all the components present 
in CaOD drug, Alltima C-18 column (250 X 4.6 mm, 
5µm) was used for the HPLC analysis. The column 
temperature was maintained at 25 °C for the whole 
duration of analysis. 
 
Preparation of mobile phase  
The buffer solution was prepared by the 
dissolution of 0.01 M (1.36 g) KH2PO4 in 980 mL 
of HPLC grade water and the pH was adjusted to 
2.7 using orthophosphoric acid followed by a final 
dilution to a volume of 1000 mL with HPLC grade 
water. The mobile phase was prepared by mixing 
together the buffer solution and HPLC grade 
acetonitrile at a ratio of 98:2 v/v. The prepared 
mobile phase was filtered through a 0.45 μ filter 
paper and degassed prior to use. 
 
Standard and sample preparation 
Stock solution of standard CaOD was prepared 
by the dissolution 50.0 mg of substance in 25 mL 
of hot water, followed by cooled and made up to  
50 mL with HPLC grade water. Further dilution 
was carried out by pipetting out of 5 mL of the 
stock solution into 50 mL standard flask and made 
up to the mark using water (Stock solution A). 
Similarly, stock solution of uracil was prepared by 
dissolving 50.0 mg of substance in 25 mL of water 
and made up to 50 mL with water. A volume of 5 
mL of the said solution of uracil was diluted to 50 
mL with water (Stock solution B). Reference 
solution was prepared by pipetting out 1.5 mL of 
stock solution A and 1.0 mL of stock solution B in 
to a 100 mL volumetric flask and made up to the 
 
Fig. 1 ― Applications of CaOD drug in osteoporosis 




mark with mobile phase. CaOD test solution was 
prepared by dissolving about 50.0 mg of substance 
in 25 mL of hot water, allowed to cool steadily and 
then made up to 100 mL with mobile phase. 
 
Spiked sample preparation 
Spiked solution was prepared by dissolving 
about 50 mg of CaOD substance in 25 ml of water 
taken in a 100 mL standard flask and dissolved the 
content by heating. To this solution, 0.5 mL of 
stock solution B was added followed by diluted up 
to 100 mL with mobile phase. 
 
Chromatographic condition 
An isocratic system of mobile phase consists of 
buffer and acetonitrile at a ratio of 98:2 v/v was 
found to be optimized condition for the related 
substance analysis of CaOD drug. The injection 
volume was fixed to 10 μL for both the standards 
and samples. The flow rate of mobile phase was  
set to 1.0 mL/min through C-18 column and  
UV detection was monitored at a wavelength of  
205 nm. The HPLC column was conditioned with 
mobile phase for 1 h prior to analysis. 
 
Results and Discussion 
HPLC method development 
Identification of impurity is the process of 
elucidating the nature of known or unknown 
materials exist in a drug sample. It is important from a 
pharmaceutical point of view to quantify both CaOD 
and the impurities present in the final product. 
Developing a method to investigate the impurities 
will aid in the quality control process of the drug 
molecule. CaOD is slightly soluble in water and 
practically insoluble in methanol and ethanol. The 
pKa value of orotic acid is 2.83
(Ref. 23)
 which suggest a 
pH of buffer solution should be 2.83±1. In order to 
find out the optimum mobile phase condition to get 
neat chromatograms, the method was screened for 
various compositions of buffer and acetonitrile. 
Three different combination of mobile phases 
were prepared by mixing buffer and acetonitrile  
in a ratio of i) 90:10 v/v, ii) 95:5 v/v and iii) 98:2 
v/v. Finally, 0.01 M KH2PO4, pH adjusted to 2.7 
with orthophosphoric acid and acetonitrile in a ratio 
of 98:2 v/v showed sharp chromatographic peaks 
with superior resolution between CaOD and 
impurity. Similarly, trials were carried out to find 
out the maximum absorbance (λmax) of CaOD drug 
and impurity at different wavelengths such as  
i) 275 nm, ii) 258 nm, iii) 210 nm and iv) 205 nm. 
UV spectra of standard calcium orotatedihydrate 
and uracil were shown in Supplementary Data, Fig. 
S1 and Fig. S2, respectively. Fig. S1 displays two 
maximum absorbance at 206.82 nm and 277.28 nm, 
whereas Fig. S2 shows the absorbance maximum at 
201.45 nm and 258.45 nm. 
The analytical results demonstrated that adequate 
response obtained for both CaOD drug and 
impurity at λmax of 205 nm with selected mobile 
phase condition of 98:2 v/v. Typical HPLC 
chromatograms of standard and sample calcium 
orotatedihydrate are presented in Fig. 2 and Fig. 3, 
respectively. A sharp peak obtained at the retention 
time of 4.83 min was corresponded to the CaOD. 
Along with the main peak, one additional peak was 
eluted at the retention time of 6.02 min. 
 




Fig. 3 ― Chromatogram of sample CaOD 




Based on the synthetic route of CaOD, it may be 
assumed that the eluted impurity in Fig. 3 is either 
uracil or unknown impurity. Hence, uracil was 
analysed by the same method and the retention time 
was found to be 6.02 min. Further, uracil was 
spiked in to CaOD sample and analysed under the 
same condition of chromatographic system. Fig. 4 
depicts the HPLC chromatogram of test solution 
spiked with 0.1 % uracil. From the results, it may 
be concluded that the eluted impurity is uracil.  
The HPLC chromatogram of reference solution  
C is presented in Fig. 5. It can be seen from  
Fig. 5 that a good resolution was observed between 
CaOD and uracil. Further, the developed method 
has been validated according to ICH guidelines. 
Two drug samples were tested for impurity 





In order to evaluate the absence of interference 
in CaOD drug, the specificity of HPLC method was 
conducted. To prove the specificity of the 
developed analytical method, blank (mobile phase), 
test solution and reference solution C were injected 
into the chromatographic system. There were no 
interference peaks observed at retention time of 
CaOD and uracil. From this experiment it can be 
concluded that the method was specific with 
respect to any interference peak. 
 
Accuracy 
Accuracy of the method was demonstrated by 
injecting the standard at 50%, 100% and 150% 
level with respect to the analyte concentration. 
Accuracy solution was prepared in triplicate at each 
level and injected each preparation once into 
chromatographic system. The accuracy data 
received from the chromatograms of CaOD and 
uracil are presented in Table 1 and Table 2 
respectively. The percentage recovery of CaOD 
and uracil was found in the range between 98 % 
and 102 %. Hence, the method is found to be 
accurate. 
 
Linearity and range 
The linearity of an analytical procedure is 
directly proportional to the analyte concentration 
of a sample
24
. From the stock solution of  
CaOD, five different concentrations (0.37 μg/mL, 
0.75 μg/mL, 1.13 μg/mL, 1.50 μg/mL and  
2.25 μg/mL) were prepared. All the solutions 
were filtered through 0.45 μ filter paper before 
loaded in to the chromatographic system. To 
evaluate the linearity, the resultant average peak 
areas of CaOD and uracil were plotted against 
the respective concentrations. The linearity data 
of the CaOD drug and uracil were provided in 
Supplementary Data, Table S1 and Table S2, 
respectively. The correlation coefficient was 
found to be more than 0.999. The calibration data 
of CaOD and uracil are displayed in Fig. 6. The 
results indicate that the method was found to be 
linear for the drug CaOD and uracil from 25% 




Fig. 4 ― Chromatogram of test solution spiked with uracil 
 
 
Fig. 5 ― Chromatogram of reference solution C 





Fig. 6 ― Linearity calibration of CaOD and uracil 
 
Precision 
The precision repeatability of an analytical 
procedure expresses the closeness of agreement 
between a series of measurements obtained from 
multiple sampling of the same homogeneous 
sample under the same operating conditions  
over a short interval of time. The precision was 
tested with the same sample by taking  six  weights  
Table 3 ― Precision repeatability data of CaOD and uracil 
Test solution Area of CaOD Area of uracil 
Sample 1 17521.490 5.214 
Sample 2 17568.129 5.353 
Sample 3 17541.049 5.384 
Sample 4 17535.102 5.419 
Sample 5 17458.279 5.371 
Sample 6 17522.998 5.158 
Average 17524.508 5.321 
% RSD 0.2 1.9 
RSD - Relative standard deviation 
 
and injected each one. Table 3 presents the 
precision data of CaOD and uracil, where the 
%RSD was found to be less than 2.0 for both 
CaOD and uracil. 
 
Limit of detection (LOD) and limit of quantification (LOQ) 
The determination of signal-to-noise ratio is 
performed by comparing the measured signals of 
the analytes in the reference solution with those of 
blank runs in mobile phase and establishing the 
minimum concentration at which the analyte can 
Table 1 ― Recovery results of CaOD 







Amount of CaOD 
(μg/mL) 
Amount of CaOD 
recovered 
(μg/mL) 
Recovery (%) Statistical 
parameters 
50 
0.5024 0.7536 1.256 1.2668 100.86 Mean: 100.69  
SD: 0.51 
RSD: 0.50 
0.5024 0.7536 1.256 1.2697 101.09 
0.5024 0.7536 1.256 1.2575 100.12 
100 
0.5024 1.5072 2.0096 2.0051 99.78 Mean: 99.65  
SD: 0.26 
RSD: 0.26 
0.5024 1.5072 2.0096 2.0060 99.82 
0.5024 1.5072 2.0096 1.9966 99.35 
150 
0.5024 2.2608 2.7632 2.7420 99.23 Mean: 99.48  
SD: 0.26 
RSD: 0.26 
0.5024 2.2608 2.7632 2.7562 99.75 
0.5024 2.2608 2.7632 2.7481 99.45 
SD - Standard deviation; RSD - Relative standard deviation 
 
 
Table 2 ― Recovery results of uracil 
Spike level (%) Sample concentration 
(mg/mL) 
Amount of uracil 
added (μg/mL) 
Amount of uracil 
recovered (μg/mL) 
Recovery (%) Statistical 
parameters 
50 
0.5016 0.5084 0.5033 99.01 Mean: 99.72  
SD: 1.36 
RSD: 1.36 
0.5016 0.5084 0.5026 98.86 
0.5016 0.5084 0.5149 101.28 
100 
0.5016 1.0168 1.0118 99.51 Mean: 100.19  
SD: 0.83 
RSD: 0.83 
0.5016 1.0168 1.0162 99.94 
0.5016 1.0168 1.0281 101.11 
150 
0.5016 1.5252 1.5356 100.68 Mean: 100.23  
SD: 0.46 
RSD: 0.46 
0.5016 1.5252 1.5292 100.26 
0.5016 1.5252 1.5215 99.76 
SD - Standard deviation; RSD - Relative standard deviation 
 




be reliably detected. The LOD was calculated with 
the signal-to-noise ratio 3:1. The determination of 
signal-to-noise ratio is performed by comparing 
the measured signals of the analytes in the 
reference solution with those of blank runs in 
mobile phase and establishing the minimum level 
at which the analyte can be quantified with 
acceptable accuracy and precision. Table 4 shows 
the LOD and LOQ values of both CaOD and 
uracil. The LOQ was calculated with the signal-to-




Solution stability was established by leaving 
the blank, reference and test solution in tightly 
closed volumetric flask at room temperature on a 
laboratory bench for 48 h. The content of CaOD 
and uracil was checked after 24 h and 48 h 
against the freshly prepared. Day to day area 
changes were observed with respect to initial  
area (0
th
 h) and % RSD was found to be less  
than 1.0. This Low value of RSD indicates that 
the reference and test solutions are stable up  
to 48 h. 
 
System suitability 
System performance of the developed HPLC 
method was investigated by injecting standard 
solutions. In order to assess the suitability of  
the system, parameters such as theoretical  
plates (N) and tailing factor (Tf) were determined. 
The results of such system suitability parameters 
for CaOD and uracil are presented in Table 5.  
It can be concluded from the data that the 
parameters indicate good performance of the 




Robustness of the method was performed by 
deliberate modification of flow rate and variation 
of pH in a mobile phase composition separately by 
keeping other parameter intact. Two types of 
variations such as (i) change in flow rate by  
± 0.2 mL /min and (ii) change of pH in  mobile 
phase composition by ±0.3 were carried out. The 
effects of the change in parameters were studied 
and found that the method was well adapted to 
accept slight changes in the retention times as 
shown in Table 6. The analytical results proved that 
the method is robust. 
 
Conclusions 
Newly developed RP-HPLC method is 
appropriate to separate the impurity present in 
calcium orotate dehydrate bulk drug. The method 
was developed using an isocratic condition of 
mobile phase consists of 0.01 M potassium 
dihydrogen orthophosphate, pH adjusted to 2.7 
with orthophosphoric acid and acetonitrile in a ratio 
of 98:2 v/v. In HPLC analysis, the retention time of 
uracil was observed at about 6.02 min in both the 
reference and CaOD sample. The developed 
analytical method has been achieved superior 
resolution (6.32) between the impurity and CaOD.It 
can be concluded from the HPLC chromatograms 
that the impurity eluted from CaOD sample is 
uracil. The resultant statistical data along with low 
RSD values (< 2.0 %) proved that the method is 
precise, specific, linear, robust and accurate. The 
developed analytical method was validated 
according to ICH guidelines and found to be 
Table 5 — System suitability studies of CaOD and uracil 











Peak area 48.73 0.7 56.73 0.4 < 2.0 % 
Retention time 
(min.) 
4.95 0.3 6.15 0.3 < 2.0 % 
Tailing factor 0.94 1.2 0.92 0.8 ≤ 2.0 
Theoretical 
plate 
12841 0.2 13502 0.2 ≥ 2000 
 
 
Table 6 ― Results of robustness study 
Conditions RT of 
CaOD 
(min.) 






Flow rate  
(0.8 mL/min) 
6.31 8.03 13077 0.89 
Flow rate  
(1.0 mL/min) 
4.83 6.02 12682 0.94 
Flow rate  
(1.2 mL/min) 
4.16 5.29 9401 0.92 
pH study @ 2.4 5.51 6.12 12859 0.87 
pH study @ 2.7 4.95 6.34 10280 0.87 
pH study @ 3.0 4.13 5.51 10216 0.89 
RT - Retention time 
Table 4 ― LOD and LOQ results 
Parameters CaOD Uracil 
LOD (%) 0.008 0.005 
LOQ - Theoretical (%) 0.028 0.018 
LOQ - Practical (%) 0.028 0.018 




applicable for the determination of uracil in CaOD 
drug. The advantages of the reported RP-HPLC 
method is economical, reproducible, sensitive and 
simplicity of sample preparation. Hence, this 
method can be effectively applied for routine 
quality control analysis for the quantification of 
impurity in CaOD drug and for impurity profiling 
of Generic drug calcium orotate. 
 
Supplementary Data 
Supplementary Data associated with this  





The authors are thankful to Synthiya Research 
Labs Private Limited, Pondicherry, India for 
providing the laboratory facility. 
 
References 
1 Wang X, Zhang Z, Xu H, Lia X & Hao X, RSC Adv.,  
10 (2020) 11624. 
2 Cai X X, Zhao L N, Wang S Y & Pingfan R, Food Funct, 
6 (2015) 816. 
3 Zhao N N, Hu J, Hou T, Ma Z L, Wang C & He H, J Func 
Foods, 8 (2014) 234. 
4 Bess D H, Dallal G E, Krall E A, Sadowski L, Sadowski L, 
Sahyoun N & Tannenbaum S, New Engl J Med,  
323 (1990) 878. 
5 Ai T, Shang L,  He C, Teng Y, Ren C,  Zhou P,  Wang L,  
Li J & Li B, Food Funct, 10 (2019) 6429. 
6 Singh G & Muthukumarappan K, LWT - Food Science 
and Technology, 41 (2008) 1145. 
7 Adluri R S, Zhan L, Bagchi M, Maulik N & Maulik G, 
Mol Cell Biochem,340 (2010) 73. 
8 Xixi C, Lina Z, Shaoyun W & Pingfan R, Food Funct,  
6 (2015) 816.  
9 Hai J, Tan X, Yang S, Chen F, Li T, Yang X, Zhu Y & 
Wang B, Dalton Trans, 48 (2019) 5735. 
10 Aguilar F, Charrondiere U R, Dusemund B, Galtier P, 
Gilbert J, Gott D M, Grilli S, Gürtler R, Kass G E N, König J, 
Lambré C, Larsen J-C, Leblanc J-C, Mortensen A, 
Parent‐Massin D, Pratt I, Rietjens I M C M, Stankovic I, 
Tobback P, Verguieva T & Woutersen R A, The EFSA 
Journal, 1187 (2009) 1. 
11 Asahi S & Doi M, Biosci Biotech Biochem, 57 (1993), 
1014. 
12 Jahan M S, Islam M H, Khan M R, Hossain A, Kayesh R 
& Rahman A, J Res Anal, 2 (2016)1. 
13 Nieper H A, Agressologie, 10 (1969) 349. 
14 Nieper H A, Agressologie, 11 (1970) 445. 
15 Saravanan M, Kumar K S, Reddy P P & Satyanarayana B, 
Synth Commun, 40 (2010) 1880. 
16 RaghavaRaju T V, Kumar S R, Srinivas A, Anil Kumar N, 
Rao I M & Rao N S, J Liq Chromatogr RT, 37 (2014) 
498. 
17 Kaul N, Agarwal H, Patil B, Kakad A & Dhaneshwar S R, 
Chromatographia, 60 (2004) 501. 
18 Hewitt E F, Lukulay P & Galushko S, J Chromatogr 
A,1107 (2006) 79. 
19 Huang G, Mingxiao Z, Jiaxing S, Yuqi B, Ling L, 
Zhenzhen X, Yuxin H, Hua L & Bin Y, Anal Lett,  
53 (2020) 2145.  
20 Liu G, Luan B, Liang G, Xing L, Huang L, Wang C & Xu 
Y, J Chromatogr A, 1571 (2018) 155. 
21 Ozdogan N, Yener B, Zaman B T & Bakirdere S, Anal 
Lett, 53 (2020) 2047. 
22 Lemasson E, Bertin S, Hennig P, Lesellier E & Westa C,  
J Chromatogr A, 1535 (2018) 101. 
23 International Conference on Harmonisation (ICH), Q2B, 
Validation of Analytical Procedures: Methodology (1997). 
24 International Conference on Harmonisation (ICH), Q2R1 
Validation of Analytical Procedures: Text and 
Methodology (2005). 
 
